Combined immune checkpoint blockage (ICB) targeting the cytotoxic T lymphocyte–associated protein 4 (CTLA-4) and PD-1, has shown great efficacy in the treatment of metastasized malignant melanoma [10] and renal cell carcinoma [11]. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.